Translation and/or Commercialization of Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Research SBIR [R43/R44]

The summary for the Translation and/or Commercialization of Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Research SBIR [R43/R44] grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Translation and/or Commercialization of Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Research SBIR [R43/R44]: Purpose. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) issues this Funding Opportunity Announcement (FOA) to solicit Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to accelerate translation and/or commercialization of musculoskeletal and skin tissue engineering and regenerative medicine research. The focus of this FOA is on pre-clinical studies with potential to immediately lead to phase I human clinical trials, or on development of pre-clinical animal models to assess safety and efficacy of potential commercial products in musculoskeletal and skin tissue engineering and regenerative medicine. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I and Phase II. This FOA does not support Fast Track applications. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 3-5 projects awarded as a result of this announcement is $1.5 million total costs for fiscal year 2010. Future year amounts will depend on annual appropriations.

Federal Grant Title:	Translation and/or Commercialization of Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Research SBIR [R43/R44]
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AR-10-004
Type of Funding:	Grant
CFDA Numbers:	93.846
CFDA Descriptions:	Arthritis, Musculoskeletal and Skin Diseases Research
Current Application Deadline:	Nov 19, 2009
Original Application Deadline:	Nov 19, 2009
Posted Date:	Apr 24, 2009
Creation Date:	Apr 24, 2009
Archive Date:	Dec 20, 2009
Total Program Funding:	$1,500,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 ...; • Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 ...; • Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Cli...; • Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed); • NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed); • Collaborative Arthritis and Musculoskeletal and Skin Diseases Science Award (Camssa); • Niams Small Grant Program for New Investigators; • Skin Diseases Research Core Centers
More Grants from the National Institutes of Health: • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...; • Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Agi...